About FibrosIX

Fibrosis encompasses a myriad of diseases that can result in morbidity and contributes to the majority of all deaths.

At FibrosIX, we are preventing fibrosis through innovative therapeutics.

FibrosIX is a pre-clinical stage biotechnology start-up, founded in 2016. It is developing proprietary first-in-class small-molecule therapeutics that inhibit fibrotic disease. These drugs modulate a critical signaling pathway that plays a central role in the pathogenesis of fibrotic disease.

The lead drug candidate, FBX081, is being developed for the prevention of lung fibrosis in cancer patients induced by chemotherapy (bleomycin) and/or radiation therapy.

Learn More About Our Work

Watch the Introduction to Fibrosix Video

fibrosis

[fahy-broh-sis]

noun Pathology.

the thickening and scarring of connective tissue, usually as a result of injury.

ORIGIN
late 19th century from Latin fibra + -osis

FibrosIX

[fahy-broh-six]

noun Pre-clinical stage biotechnology start-up.

a company dedicated to preventing fibrosis through innovative therapeutics.

ORIGIN
founded in 2016, Lansing, Michigan

Latest News from FibrosIX

Read More News